Nautilus Biotechnology (NASDAQ:NAUT) Trading Down 5.9% – Here’s Why

Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) dropped 5.9% during mid-day trading on Tuesday . The stock traded as low as $1.57 and last traded at $1.60. Approximately 119,589 shares traded hands during mid-day trading, an increase of 4% from the average daily volume of 114,703 shares. The stock had previously closed at $1.70.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group lowered Nautilus Biotechnology from a “neutral” rating to a “sell” rating and reduced their target price for the stock from $2.25 to $1.75 in a report on Thursday, December 5th.

Nautilus Biotechnology Trading Down 5.9 %

The firm has a market capitalization of $200.90 million, a P/E ratio of -2.86 and a beta of 1.21. The stock’s 50-day simple moving average is $1.84 and its 200-day simple moving average is $2.33.

Institutional Investors Weigh In On Nautilus Biotechnology

Institutional investors have recently added to or reduced their stakes in the business. Barclays PLC grew its position in shares of Nautilus Biotechnology by 79.6% in the third quarter. Barclays PLC now owns 106,174 shares of the company’s stock valued at $303,000 after purchasing an additional 47,059 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in Nautilus Biotechnology in the 3rd quarter worth about $67,000. MetLife Investment Management LLC purchased a new position in Nautilus Biotechnology during the 3rd quarter valued at about $87,000. China Universal Asset Management Co. Ltd. increased its position in shares of Nautilus Biotechnology by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock valued at $69,000 after buying an additional 9,404 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of Nautilus Biotechnology in the third quarter worth about $50,000. 50.71% of the stock is owned by hedge funds and other institutional investors.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.